HNK-1+ cells in non-Hodgkin's lymphoma: lack of relation with transferrin receptor expression on malignant cells.

por Schuurman, H. J., Kluin, P. M., de Gast, G. C., Kater, L.
Publicado 1985

B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease.

por Vooijs, W. C., Otten, H. G., van Vliet, M., van Dijk, A. J., de Weger, R. A., de Boer, M., Bohlen, H., Bolognesi, A., Polito, L., de Gast, G. C.
Publicado 1997

Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanoma

por de Gast, G C, Batchelor, D, Kersten, M J, Vyth-Dreese, F A, Sein, J, van de Kasteele, W F, Nooijen, W J, Nieweg, O E, Waal, M A de, Boogerd, W
Publicado 2003

Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma

por Verra, N, Jansen, R, Groenewegen, G, Mallo, H, Kersten, M J, Bex, A, Vyth-Dreese, F A, Sein, J, van de Kasteele, W, Nooijen, W J, de Waal, M, Horenblas, S, de Gast, G C
Publicado 2003